TROG 17.06 - SC.24 - TROG Cancer Research

By w.paterson
23 June, 2021
0 Comments

A Phase III Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) For Patients With Spinal Metastases

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Clinical Trial Registration

Registration Link

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase III Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) For Patients With Spinal Metastases

EORTC 22033-26033/TROG 06.01 (Low Grade Glioma)

UON/TROG 12.03 – EAT

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000

TROG 17.06 – SC.24

A Phase III Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) For Patients With Spinal Metastases

EORTC 22033-26033/TROG 06.01 (Low Grade Glioma)

UON/TROG 12.03 – EAT

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000